Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Get access
    Buy the print book
    Check if you have access via personal or institutional login
    Log in Register Recommend to librarian
  • Cited by 3
  • Cited by
    Crossref Citations
    Crossref logo
    This (lowercase (translateProductType product.productType)) has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Paduch, Marcin and Kossiakoff, Anthony A. 2017. Synthetic Antibodies. Vol. 1575, Issue. , p. 93.
    Nikoloudis, Dimitris Pitts, Jim E. and Saldanha, José W. 2014. A complete, multi-level conformational clustering of antibody complementarity-determining regions. PeerJ, Vol. 2, Issue. , p. e456.
    Wang, Xiangdan Quarmby, Valerie Ng, Carl Chuntharapai, Anan Shek, Theresa Eigenbrot, Charles Kelley, Robert F. Shia, Steven McCutcheon, Krista M Lowe, John Leddy, Cecilia Coachman, Kyle Cain, Gary Chu, Felix Hotzel, Isidro Maia, Mauricio Wakshull, Eric and Yang, Jihong 2013. Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG. mAbs, Vol. 5, Issue. 4, p. 540.
    ×
  • Print publication year: 2009
  • Online publication date: December 2009

1 - Humanization of Recombinant Antibodies

from PART I - HUMANIZED ANTIBODIES
Export citation
Summary

Since 1890, when von Behring and Kitasato reported that animal antitoxin serum could protect against lethal doses of toxins in humans, antisera have been used to neutralize pathogens in acute disease as well as in prophylaxis. Antisera are also used in vitro as diagnostic tools to establish and monitor disease. However, antisera invariably induce an immune response resulting in joint pains, fevers, and sometimes life-threatening anaphylactic shock. Various proteins contribute to the immunogenicity, as the serum is a crude extract containing not only the antibodies against the disease-causing antigen (often at low concentration), but also other antibodies and proteins.

FULLY MOUSE TO FULLY HUMAN

In 1975, Köhler and Milstein (1975) at the Medical Research Council's (MRC) Laboratory of Molecular Biology in Cambridge (UK) reported their discovery of a way to produce custom-built antibodies in vitro with relative ease. They fused rodent antibody-producing cells with immortal tumor cells (myelomas) from the bone marrow of mice to produce hybridomas. A hybridoma combines the cancer cell's ability to reproduce almost indefinitely with the immune cell's ability to produce antibodies. Once screened to isolate the hybridomas yielding antibodies of the required antigen specificity and affinity – and given the right nutrients – a hybridoma will grow and divide, mass-producing antibodies of a single type (monoclonals). Nearly a century before, the German scientist Paul Ehrlich envisaged that such entities could be used as magic bullets to target and destroy human diseases, and hybridomas seemed like a production line of batch consistency for these magic bullets.

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Recombinant Antibodies for Immunotherapy
  • Online ISBN: 9780511596773
  • Book DOI: https://doi.org/10.1017/CBO9780511596773
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×
REFERENCES
Al-Lazikani, B, Lesk, AM, Chothia, C. (1997) Standard conformations for the canonical structure of immunoglobulins. J. Mol. Biol. 273, 927–48.
Baca, M, Presta, LG, O'Connor, SJ, Wells, JA. (1997) Antibody humanization using monovalent phage display. J. Biol. Chem. 272, 10678–84.
Boulianne, GL, Hozumi, N, Shulman, MJ. (1984) Production of functional chimaeric mouse/human antibody. Nature. 312, 643–6.
Bourne, PC, Terzyan, SS, Cloud, G, Landolfi, NF, Vasquez, M, Edmundson, AB. (2004) Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms. Acta Crystallogr. D. Biol Crystallogr. 60, 1761–9.
Brüggemann, M, Spicer, C, Buluwela, L, Rosewell, I, Barton, S, Surani, MA, Rabbitts, TH. (1991) Human antibody production in transgenic mice: expression from 100kb of the human IgH locus. Eur. J. Immunol. 21, 1323–6.
Brüggemann, M, Winter, G, Waldmann, H, Neuberger, MS. (1989) The immunogenicity of chimeric antibodies. J. Exp. Med. 170, 2153–7.
Chothia, C, Lesk, AM, Tramontano, A, Levitt, M, Smith-Gill, SJ, Air, G, Sheriff, S, Padlan, EA, Davies, D, Tulip, WR, Colman, PM, Spinelli, S, Alzari, PM, Poljak, RJ. (1989) Conformations of immunoglobulin hypervariable regions. Nature 342, 877–83.
Chothia, C, Lesk, AM. (1987) Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901–17.
Chothia, C, Novotny, J, Bruccoleri, R, Karplus, M. (1985) Domain association in immunoglobulin molecules. The packing of variable domains. J. Mol. Biol. 186, 651–63.
Co, MS, Deschamps, M, Whitley, RJ, Queen, C. (1991) Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 2869–73.
Co, MS, Scheinberg, DA, Avdalovic, NM, McGraw, K, Vasquez, M, Caron, PC, Queen, C. (1993) Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol. Immunol. 30, 1361–7.
Dall'Acqua, WF, Damschroder, MM, Zhang, J, Woods, RM, Widjaja, L, Yu, J, Wu, H. (2005) Antibody humanization by framework shuffling. Methods 36, 43–60.
Damschroder, MM, Widjaja, L, Gill, PS, Krasnoperov, V, Jiang, W, Dall'Acqua, WF, Wu, H. (2007) Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol. Immunol. 44, 3049–60.
Daugherty, BL, DeMartino, JA, Law, MF, Kawka, DW, Singer, II, Mark, GE. (1991) Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 19, 2471–6.
Ellis, JH, Barber, KA, Tutt, A, Hale, C, Lewis, AP, Glennie, MJ, Stevenson, GT, Crowe, JS. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155, 925–37.
Fontayne, A, Vanhoorelbeke, K, Pareyn, I, Rompaey, I, Meiring, M, Lamprecht, S, Roodt, J, Desmet, J, Deckmyn, H. (2006) Rational humanization of the powerful antithrombotic anti-GPIbα antibody: 6B4. Thromb. Haemost. 96, 671–84.
Gonzales, NR, Padlan, EA, Pascalis, R, Schuck, P, Schlom, J, Kashmiri, SV. (2004) SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol. Immunol. 41, 863–72.
Gorman, SD, Clark, MR, Routledge, EG, Cobbold, SP, Waldmann, H. (1991) Reshaping a therapeutic CD4 antibody. Proc. Natl. Acad. Sci. U.S.A. 88, 4181–5.
Graziano, RF, Tempest, PR, White, P, Keler, T, Deo, Y, Ghebremariam, H, Coleman, K, Pfefferkorn, LC, Fanger, MW, Guyre, PM. (1995) Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J. Immunol. 155, 4996–5002.
Hakimi, J, Ha, VC, Lin, P, Campbell, E, Gately, MK, Tsudo, M, Payne, PW, Waldmann, TA, Grant, AJ, Tsien, WH, Schneider, WP. (1993) Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC. J. Immunol. 151, 1075–85.
Hamilton, AA, Manuel, DM, Grundy, JE, Turner, AJ, King, SI, Adair, JR, White, P, Carr, FJ, Harris, WJ. (1997) A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. J. Infect. Dis. 176, 59–68.
Hellendoorn, K, Jones, T, Watkins, J, Baker, M, Hamilton, A, Carr, F. (2004) Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™). Cancer Cell Intl. 4, S20.
Hwang, WY, Foote, J. (2005) Immunogenicity of engineered antibodies. Methods 36, 3–10.
Jaffers, GJ, Fuller, TC, Cosimi, AB, Russell, PS, Winn, HJ, Colvin, RB. (1986) Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41, 572–8.
Jensen, M, Klehr, M, Bogel, A, Schmitz, S, Tawadros, S, Mühlenhoff, M, Plück, A, Fischer, T, Schomäcker, K, Schultze, JL, Berthold, F. (2007) One step generation of fully chimeric antibodies using Cγ1- and Cκ mutant mice. J. Immunother. 30, 338–49.
Jespers, LS, Roberts, A, Mahler, SM, Winter, G, Hoogenboom, HR. (1994) Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology 12, 899–903.
Jones, PT, Dear, PH, Foote, J, Neuberger, MS, Winter, G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–5.
Junghans, RP, Waldmann, TA, Landolfi, NF, Avdalovic, NM, Schneider, WP, Queen, C. (1990) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50, 1495–502.
Kabat, EA, Wu, TT, Perry, H, Gottesman, K, Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th ed. NIH Publication No. 91–3242.
Kabat, EA, Wu, TT, Reid-Miller, M, Perry, H, Gottesman, K. (1987) Sequences of Proteins of Immunological Interest, 4th ed. US Govt. Printing Office No. 165–492.
Kettleborough, CA, Saldanha, J, Heath, VJ, Morrison, CJ, Bendig, MM. (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4, 773–83.
Köhler, G, Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–7.
Kolbinger, F, Saldanha, J, Hardman, N, Bendig, MM. (1993) Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng. 6, 971–80.
Lazar, GA, Desjarlais, JR, Jacinto, J, Karki, S, Hammond, PW. (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol. 44, 1986–1998.
Léger, OJ, Yednock, TA, Tanner, L, Horner, HC, Hines, DK, Keen, S, Saldanha, J, Jones, ST, Fritz, LC, Bendig, MM. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3–16.
Li, J, Sai, T, Berger, M, Chao, Q, Davidson, D, et al. (2006) Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc. Natl. Acad. Sci. U.S.A. 103, 3557–62.
Lv, M, Li, Y, Yu, M, Sun, Y, Lin, Z, Qiao, C, Luo, Q, Gu, X, Huang, Y, Feng, J, Shen, B. (2007) Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design. Int. J. Biochem. Cell Biol. 39, 1142–55.
Maeda, H, Matsushita, S, Eda, Y, Kimachi, K, Tokiyoshi, S, Bendig, MM. (1991) Construction of reshaped human antibodies with HIV-neutralizing activity. Hum. Antibodies Hybridomas. 2, 124–34.
McCafferty, J, Griffiths, AD, Winter, G, Chiswell, DJ. (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–4.
Morelock, MM, Rothlein, R, Bright, SM, Robinson, MK, Graham, ET, Sabo, JP, Owens, R, King, DJ, Norris, SH, Scher, DS, et al. (1994) Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem. 269, 13048–55.
Morrison, SL, Johnson, MJ, Herzenberg, , Oi, VT. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 81, 6851–5.
Nakamura, K, Tanaka, Y, Fujino, I, Hirayama, N, Shitara, K, Hanai, N. (2000) Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol. Immunol. 37, 1035–46.
Neuberger, MS, Williams, GT, Mitchell, EB, Jouhal, SS, Flanagan, JG, Rabbitts, TH. (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314, 268–70.
Nisihara, T, Ushio, Y, Higuchi, H, Kayagaki, N, Yamaguchi, N, Soejima, K, Matsuo, S, Maeda, H, Eda, Y, Okumura, K, Yagita, H. (2001) Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction. J. Immunol. 167, 3266–75.
Ohlin, M, Owman, H, Mach, M, Borrebaeck, CA. (1996) Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol. Immunol. 33, 47–56.
Padlan, EA, Abergel, C, Tipper, JP. (1995) Identification of specificity-determining residues in antibodies. FASEB J. 9, 133–9.
Padlan, EA. (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28, 489–98.
Padlan, EA. (1994) Anatomy of the antibody molecule. Mol. Immunol. 31, 169–217.
Pedersen, JT, Henry, AH, Searle, SJ, Guild, BC, Roguska, M, Rees, AR. (1994) Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J. Mol. Biol. 235, 959–73.
Poul, MA, Ticchioni, M, Bernard, A, Lefranc, MP. (1995) Inhibition of T cell activation with a humanized anti-beta 1 integrin chain mAb. Mol. Immunol. 32, 101–16.
Queen, C, Schneider, WP, Selick, HE, Payne, PW, Landolfi, NF, Duncan, JF, Avdalovic, NM, Levitt, M, Junghans, RP, Waldmann, TA. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U.S.A. 86, 10029–33.
Rader, C, Cheresh, DA, Barbas, CF. (1998) A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Natl. Acad. Sci. U.S.A. 95, 8910–5.
Riechmann, L, Clark, M, Waldmann, H, Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323–7.
Rodrigues, ML, Shalaby, MR, Werther, W, Presta, L, Carter, P. (1992) Engineering a humanized bispecific F(ab′)2 fragment for improved binding to T cells. Int J Cancer Suppl. 7, 45–50.
Rosok, MJ, Yelton, , Harris, LJ, Bajorath, J, Hellstrom, KE, Hellstrom, I, Cruz, GA, Kristensson, K, Lin, H, Huse, WD, Glaser, SM. (1996) A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J. Biol. Chem. 271, 22611–8.
Saldanha, JW, Martin, AC, Léger, OJ. (1999) A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells. Mol. Immunol. 36, 709–19.
Sato, K, Ohtomo, T, Hirata, Y, Saito, H, Matsuura, T, Akimoto, T, Akamatsu, K, Koishihara, Y, Ohsugi, Y, Tsuchiya, M. (1996) Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Hum. Antibodies. Hybridomas 7, 175–83.
Sato, K, Tsuchiya, M, Saldanha, J, Koishihara, Y, Ohsugi, Y, Kishimoto, T, Bendig, MM. (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851–6.
Sato, K, Tsuchiya, M, Saldanha, J, Koishihara, Y, Ohsugi, Y, Kishimoto, T, Bendig, MM. (1994) Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol. Immunol. 31, 371–81.
Schneider, WP, Glaser, SM, Kondas, JA, Hakimi, J. (1993) The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J. Immunol. 150, 3086–90.
Schroff, RW, Foon, KA, Beatty, SM, Oldham, RK, Morgan, AC. (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45, 879–85.
Shearman, CW, Pollock, D, White, G, Hehir, K, Moore, GP, Kanzy, EJ, Kurrle, R. (1991) Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor. J. Immunol. 147, 4366–73.
Shirai, H, Kidera, A, Nakamura, H. (1996) Structural classification of CDR-H3 in antibodies. FEBS Lett. 399, 1–8.
Shirai, H, Kidera, A, Nakamura, H. (1999) H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett. 455, 188–97.
Staelens, S, Desmet, J, Ngo, TH, Vauterin, S, Pareyn, I, Barbeaux, P, Rompaey, I, Stassen, JM, Deckmyn, H, Vanhoorelbeke, K. (2006) Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modeling of variable domains. Mol. Immunol. 43, 1243–57.
Tan, P, Mitchell, DA, Buss, TN, Holmes, MA, Anasetti, C, Foote, J. (2002) “Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169, 1119–25.
Tempest, PR, White, P, Buttle, M, Carr, FJ, Harris, WJ. (1995) Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int. J. Biol. Macromol. 17, 37–42.
Thomas, TC, Rollins, SA, Rother, RP, Giannoni, MA, Hartman, SL, Elliott, EA, Nye, SH, Matis, , Squinto, SP, Evans, MJ. (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389–401.
Vargas-Madrazo, E, Paz-García, E. (2003) An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. J. Mol. Recognit. 16, 113–20.
Verhoeyen, M, Milstein, C, Winter, G. (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239, 1534–6.
Wu, H, Nie, Y, Huse, WD, Watkins, JD. (1999) Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151–62.
Wu, TT, Kabat, EA. (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132, 211–50.
Yoon, SO, Lee, TS, Kim, SJ, Jang, MH, Kang, YJ, Park, JH, Kim, KS, Lee, HS, Ryu, CJ, Gonzales, NR, Kasmiri, SV, Lim, SM, Choi, CW, Hong, HJ. (2006) Construction, affinity maturation and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985–92.
Zhang, W, Feng, J, Li, Y, Guo, N, Shen, B. (2005) Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling. Mol. Immunol. 42, 1445–51.
Cancel
Confirm
×